Bogle Grant C. 4
4 · Epizyme, Inc. · Filed Feb 4, 2022
Insider Transaction Report
Form 4
Epizyme, Inc.EPZM
Bogle Grant C.
Director
Transactions
- Award
Common Stock, par value $0.0001
2022-02-02+87,500→ 183,060 total - Award
Stock Option (Right to Buy)
2022-02-02+417,500→ 417,500 totalExercise: $1.41Exp: 2032-02-01→ Common Stock (417,500 underlying)
Footnotes (2)
- [F1]Consists of shares of Common Stock issuable under 87,500 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal installments, with the first installment vesting on August 16, 2022, the second installment vesting on August 16, 2023, and the third installment vesting on August 16, 2024.
- [F2]This option was granted on February 2, 2022 pursuant to the Company's 2013 Stock Incentive Plan with respect to 417,500 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.